Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
NCT04964271 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-02-02
Summary
This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of prostate cancer. Blood samples will be collected from 60 participants divided into 40 patients and 20 healthy donors.
Conditions
- Prostatic Neoplasms
Sponsors & Collaborators
-
Tethis S.p.A.
lead INDUSTRY
Principal Investigators
-
Alberto Briganti, MD · Ospedale San Raffaele
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-09-09
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- Italy
Study Locations
More Related Trials
-
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
NCT03237702 ·Status: RECRUITING ·Phase: NA
-
Investigating and Characterizing the Immune Response to Prostate Cancer
NCT03331367 ·Status: COMPLETED ·Phase: NA
-
Identification of Predictive Biomarkers
NCT04324983 ·Status: COMPLETED ·Phase: NA
-
Markers for Early Detection of Prostate Cancer
NCT00340717 ·Status: COMPLETED
-
Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer
NCT01615965 ·Status: UNKNOWN ·Phase: NA
-
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer
NCT00967889 ·Status: UNKNOWN
-
PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma
NCT00427817 ·Status: COMPLETED
-
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
NCT01672411 ·Status: COMPLETED
-
Micro-RNA Expression Profiles in High Risk Prostate Cancer
NCT01220427 ·Status: TERMINATED
-
DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
NCT07265414 ·Status: ACTIVE_NOT_RECRUITING
-
Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors
NCT04340245 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Diagnostic Performance of [18F]CTT1057 in BCR
NCT04838613 ·Status: COMPLETED ·Phase: PHASE3
-
Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer
NCT03927287 ·Status: COMPLETED
-
Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique
NCT02940977 ·Status: UNKNOWN
-
Genetic Biomarker Discovery for Metastatic Prostate Cancer
NCT03228810 ·Status: COMPLETED
-
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features
NCT04825691 ·Status: UNKNOWN
-
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
NCT03789253 ·Status: RECRUITING
-
Using PSMA PET-CT as a Diagnostic Tool for Detection of Prostatic Cancer at an Early Stage
NCT04116086 ·Status: UNKNOWN ·Phase: NA
-
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
NCT04266392 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy (HOPE)
NCT05141383 ·Status: COMPLETED ·Phase: NA
-
Early Detection of Prostate Cancer
NCT04556916 ·Status: RECRUITING ·Phase: NA
-
PSMA PET/CT vs. mpMRI in Patients With a High Suspicion of Prostate Cancer: a Head to Head, Parallel, Prospective Trial
NCT05297162 ·Status: UNKNOWN ·Phase: NA
-
PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study
NCT05806853 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
NCT03488706 ·Status: UNKNOWN
-
PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer
NCT04560725 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA